Barclays PLC Biogen Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Biogen Inc. stock. As of the latest transaction made, Barclays PLC holds 2,700 shares of BIIB stock, worth $607,338. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,700

Previous 25,800 89.53%

Holding current value

$607,338

Previous $6.68 Million 91.28%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $1.76 Million - $2.22 Million	8,305 Added 1.56%	540,565 $117 Million
Q4 2023 Feb 15, 2024	BUY	$222.59 - $267.94 $30.4 Million - $36.6 Million	136,584 Added 34.52%	532,260 $138 Million
Q3 2023 Nov 07, 2023	SELL	$253.3 - $285.89 $48.7 Million - $54.9 Million	-192,085 Reduced 32.68%	395,676 $102 Million
Q2 2023 Aug 03, 2023	BUY	$275.25 - $318.06 $35.8 Million - $41.3 Million	129,918 Added 28.38%	587,761 $167 Million
Q1 2023 May 04, 2023	SELL	$256.56 - $292.34 $42.3 Million - $48.2 Million	-164,885 Reduced 26.48%	457,843 $127 Million

Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $72.4 Million - $88 Million	286,871 Added 85.41%	622,728 $172 Million
Q3 2022 Nov 03, 2022	BUY	$194.69 - $268.46 $4.54 Million - $6.27 Million	23,342 Added 7.47%	335,857 $89.7 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $12.5 Million - $14.9 Million	-66,866 Reduced 17.63%	312,515 $63.7 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $84.7 Million - $107 Million	-437,190 Reduced 53.54%	379,381 $79.9 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $96.7 Million - $124 Million	431,657 Added 112.14%	816,571 $196 Million
Q3 2021 Nov 09, 2021	BUY	$282.99 - $369.05 $16 Million - $20.9 Million	56,681 Added 17.27%	384,914 $109 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $8.52 Million - $13.6 Million	32,878 Added 11.13%	328,233 $114 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $49.9 Million - $58.4 Million	-205,329 Reduced 41.01%	295,355 $82.6 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $19.2 Million - $29 Million	81,422 Added 19.42%	500,684 $123 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $10.7 Million - $12.3 Million	40,253 Added 10.62%	419,262 $119 Million
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $5.18 Million - $6.86 Million	-20,026 Reduced 5.02%	379,009 $101 Million
Q1 2020 May 13, 2020	SELL	$268.85 - $341.04 $71.4 Million - $90.5 Million	-265,491 Reduced 39.95%	399,035 $126 Million
Q4 2019 Feb 10, 2020	BUY	$220.06 - $304.07 $30.7 Million - $42.5 Million	139,725 Added 26.62%	664,526 $197 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $3.17 Million - $3.55 Million	14,557 Added 2.85%	524,801 $122 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $26.2 Million - $28.8 Million	119,272 Added 30.51%	510,244 $119 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $698,456 - $1.09 Million	-3,223 Reduced 0.82%	390,972 $92.4 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $15.1 Million - $19.2 Million	54,310 Added 15.98%	394,195 $119 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $3.98 Million - $5.2 Million	-13,556 Reduced 3.84%	339,885 $120 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $30.3 Million - $36.2 Million	-117,833 Reduced 25.0%	353,441 $103 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $42 Million - $59.3 Million	161,284 Added 52.03%	471,274 $129 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $48 Million - $53.8 Million	156,148 Added 101.5%	309,990 $98.8 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $43.3 Million - $50.7 Million	153,842	153,842 $48.2 Million

Others Institutions Holding BIIB

# of Institutions

1,046

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $32.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account